In the claims

1. **(currently amended)** A compound represented by formula **(I):**



(I)

wherein,

A is either a double bond or a single bond, n is 2 or 3, and each occurrence of R_1 is independently selected from the group consisting of hydrogen, aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkenyl, and alkynyl;

R_2-R_{13} each independently are selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkoxy, [[-$C(O)R_8$]] -$C(O)R_{15}$, amino, hydroxy, thio, halogen, cyano, nitro, trifluoromethyl, -N_3, [[-$C(R_8)$=NR_8; -N=$C(R_8)_2$, -$C(O)N(R_8)_2$, -Q_2-$P(Q_1)(OR_8)_2$,]] -$C(R_{15})$=NR_{15}; -N=$C(R_{15})_2$, -$C(O)N(R_{15})_2$, -Q_2-$P(Q_1)(OR_{15})_2$, -SO_2R, silyl, -$R_{16}OR_{15}$, -SR_{15}, and -CO_2R_{15} [[-R_9OR_8, -SR_8, and -CO_2R_8]];

R_{14} is selected from the group consisting of -$R_{16}C(O)OR_{15}$, -$OC(O)R_{15}$, O-R_{17}, [[-$R_9C(O)OR$, -$OC(O)R$, O-R_{15},]] wherein R_{17} [[R_{15}]] is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, alkenyl, and alkynyl; -$R_{16}(O)CR_{15}$; -$C(R_{15})$=$N(OH)$; carboxylic acid; -$R_{16}C(O)H$; -Q_2-$P(Q_1)(OR_{15})_2$; [[-$R_9(O)CR_8$; -$C(R_8)$=$N(OH)$; carboxylic acid; -$R_9C(O)H$; -Q_2-$P(Q_1)(OR_8)_2$;]] and silyl;

R_{15} [[R_8]] represents independently for each occurrence hydrogen, alkyl, alkenyl, alkynyl, or aryl;

$\underline{R_{16}}$ [[R_9]] represents independently for each occurrence a bond or an alkyl, alkenyl, alkynyl, or aryl biradical;

Q_1 represents independently for each occurrence S or O; and

Q_2 represents independently for each occurrence O, S, or $\underline{NR_{15}}$; [[NR_8;]]

or a pharmaceutically acceptable salt thereof.

2. (**currently amended**) The compound of claim 1, wherein one occurrence of R_1 is selected from the group consisting of aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkenyl, and alkynyl; A is a double bond; n = 2; at least one occurrence of R_1 is hydrogen, and the compound is an E (entgegen) or Z (zusammen) isomer; R_2-R_{13} each independently represent hydrogen or alkyl; and R_{14} is $\underline{-R_{16}C(O)OR_{15}\text{ or }-OC(O)R_{15}}$ [[-R_9C(O)OR or -OC(O)R]].

3. (**currently amended**) The compound of claim 1, wherein one occurrence of R_1 is selected from the group consisting of haloaryl, ~~alkoxy,~~ alkylaryl, polycyclyl, alkenylaryl, and alkynylaryl; and either one or two occurrences of R_1 represent hydrogen.

4. (**currently amended**) The compound of claim 1, wherein A is a double bond; n = 2; and one occurrence of R_1 is selected from the group consisting of phenyl, 3,4-Dichloro-phenyl, 4-methoxy-phenyl, 4-fluoro-phenyl, 1-napthyl, 2-furyl, 3-furyl, ~~methoxy,~~ and substituted or unsubstituted alkenylaryl, and the second occurrence of R_1 is hydrogen, and the compound is an E (entgegen) isomer.

5. (**currently amended**) The compound of claim 1, wherein one occurrence of R_1 is 4-methoxy-phenyl, one occurrence of R_1 is hydrogen; R_2-R_{13} each represent hydrogen; and R_{14} represents $\underline{-R_{16}C(O)OR_{15}\text{ or }-OC(O)R_{15}}$ [[-R_9C(O)OR or -OC(O)R]].

6. (**currently amended**) The compound of claim 1, wherein one occurrence of R_1 is phenyl, one occurrence of R_1 is hydrogen, R_2-R_{13} each represent hydrogen, and R_{14} represents $\underline{-R_{16}C(O)OR_{15}\text{ or }-OC(O)R_{15}}$ [[-R_9C(O)OR or -OC(O)R]].

7. **(currently amended)** A pharmaceutical composition comprising a compound of formula **(I):**



(I)

wherein,

A is either a double bond or a single bond, n is 2 or 3, and each occurrence of R_1 is independently selected from the group consisting of hydrogen, aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkenyl, and alkynyl;

R_2-R_{13} each independently are selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkoxy, [[-$C(O)R_8$]] $\underline{-C(O)R_{15}}$, amino, hydroxy, thio, halogen, cyano, nitro, trifluoromethyl, -N_3, [[$-C(R_8)=NR_8$; $-N=C(R_8)_2$, $-C(O)N(R_8)_2$, $-Q_2-P(Q_1)(OR_8)_2$,]] $\underline{-C(R_{15})=NR_{15}}$; $\underline{-N=C(R_{15})_2}$, $\underline{-C(O)N(R_{15})_2}$, $\underline{-Q_2-P(Q_1)(OR_{15})_2}$, $-SO_2R$, silyl, $\underline{-R_{16}OR_{15}}$, $\underline{-SR_{15}}$, and $\underline{-CO_2R_{15}}$ [[$-R_9OR_8$, $-SR_8$, and $-CO_2R_8$]];

R_{14} is selected from the group consisting of $\underline{-R_{16}C(O)OR_{15}}$, $\underline{-OC(O)R_{15}}$, $\underline{O-R_{17}}$, [[$-R_9C(O)OR$, $-OC(O)R$, $O-R_{15}$,]] wherein $\underline{R_{17}}$ [[R_{15}]] is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, alkenyl, and alkynyl; $\underline{-R_{16}(O)CR_{15}}$; $\underline{-C(R_{15})=N(OH)}$; $\underline{\text{carboxylic acid}}$; $\underline{-R_{16}C(O)H}$; $\underline{-Q_2-P(Q_1)(OR_{15})_2}$; [[$-R_9(O)CR_8$; $-C(R_8)=N(OH)$; carboxylic acid; $-R_9C(O)H$; $-Q_2-P(Q_1)(OR_8)_2$;]] and silyl;

$\underline{R_{15}}$ [[R_8]] represents independently for each occurrence hydrogen, alkyl, alkenyl, alkynyl, or aryl;

$\underline{R_{16}}$ [[R_9]] represents independently for each occurrence a bond or an alkyl, alkenyl, alkynyl, or aryl biradical;

Q_1 represents independently for each occurrence S or O; and

Q_2 represents independently for each occurrence O, S, or $\underline{NR_{15}}$; [[NR_8;]]

or a pharmaceutically acceptable salt thereof; and

a pharmaceutically acceptable carrier.

8. **(currently amended)** The pharmaceutical composition of claim 7, wherein one occurrence of R_1 is selected from the group consisting of aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkenyl, and alkynyl; A is a double bond; n = 2; at least one occurrence of R_1 is hydrogen, and the compound is an E (entgegen) or Z (zusammen) isomer; and R_2-R_{13} each independently represent hydrogen or alkyl; and R_{14} is $\underline{-R_{16}C(O)OR_{15}}$ or $\underline{-OC(O)R_{15}}$ [[$-R_9C(O)OR$ or $-OC(O)R$]].

9. **(currently amended)** The pharmaceutical composition of claim 7, wherein one occurrence of R_1 is selected from the group consisting of haloaryl, ~~alkoxy,~~ alkylaryl, polycyclyl, alkenylaryl, and alkynylaryl; and one or two occurrences of R_1 represent hydrogen.

10. **(currently amended)** The pharmaceutical composition of claim 7, wherein A is a double bond; n = 2; and one occurrence of R_1 is selected from the group consisting of phenyl, 3,4-Dichloro-phenyl, 4-methoxy-phenyl, 4-fluoro-phenyl, 1-napthyl, 2-furyl, 3-furyl, ~~methoxy,~~ and substituted or unsubstituted alkenylaryl, and the second occurrence of R_1 is hydrogen, and the compound is an E (entgegen) isomer.

11. **(currently amended)** A method for treating a disorder caused by a deficiency in monoamine concentration in a human comprising administering a therapeutically effective dose of a compound of formula **(I)**:



(I)

wherein,

A is either a double bond or a single bond, n is 2 or 3, and each occurrence of R_1 is independently selected from the group consisting of hydrogen, aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkenyl, and alkynyl;

R_2-R_{13} each independently are selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkoxy, [[-$C(O)R_8$]] -$\underline{C(O)R_{15}}$, amino, hydroxy, thio, halogen, cyano, nitro, trifluoromethyl, -N_3, [[-$C(R_8)$=NR_8; -N=$C(R_8)_2$, -$C(O)N(R_8)_2$, -Q_2-$P(Q_1)(OR_8)_2$,]] -$\underline{C(R_{15})=NR_{15}}$; -$\underline{N=C(R_{15})_2}$, -$\underline{C(O)N(R_{15})_2}$, -$\underline{Q_2\text{-}P(Q_1)(OR_{15})_2}$, -$SO_2R$, silyl, -$\underline{R_{16}OR_{15}}$, -$\underline{SR_{15}}$, and -$\underline{CO_2R_{15}}$ [[-R_9OR_8, -SR_8, and -CO_2R_8]];

R_{14} is selected from the group consisting of -$\underline{R_{16}C(O)OR_{15}}$, -$\underline{OC(O)R_{15}}$, $\underline{O\text{-}R_{17}}$, [[-$R_9C(O)OR$, -$OC(O)R$, $O\text{-}R_{15}$,]] wherein $\underline{R_{17}}$ [[R_{15}]] is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, alkenyl, and alkynyl; -$\underline{R_{16}(O)CR_{15}}$; -$\underline{C(R_{15})=N(OH)}$; carboxylic acid; -$\underline{R_{16}C(O)H}$; -$\underline{Q_2\text{-}P(Q_1)(OR_{15})_2}$; [[-$R_9(O)CR_8$; -$C(R_8)$=$N(OH)$; carboxylic acid; -$R_9C(O)H$; -$Q_2$-$P(Q_1)(OR_8)_2$;]] and silyl;

$\underline{R_{15}}$ [[R_8]] represents independently for each occurrence hydrogen, alkyl, alkenyl, alkynyl, or aryl;

$\underline{R_{16}}$ [[R_9]] represents independently for each occurrence a bond or an alkyl, alkenyl, alkynyl, or aryl biradical;

Q_1 represents independently for each occurrence S or O; and

Q_2 represents independently for each occurrence O, S, or $\underline{NR_{15}}$; [[NR_8;]]

or a pharmaceutically acceptable salt thereof.

12. (**currently amended**) The method of claim 11, wherein one occurrence of R_1 is selected from the group consisting of aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkenyl, and alkynyl; A is a double bond; n = 2; at least one occurrence of R_1 is hydrogen, and the compound is an E (entgegen) or Z (zusammen) isomer; and R_2-R_{13} each independently represent hydrogen or alkyl; and R_{14} is $\underline{-R_{16}C(O)OR_{15}}$ or $\underline{-OC(O)R_{15}}$ [[$-R_9C(O)OR$ or $-OC(O)R$]].

13. (**currently amended**) The method of claim 11, wherein one occurrence of R_1 is selected from the group consisting of haloaryl, ~~alkoxy,~~ alkylaryl, polycyclyl, alkenylaryl, and alkynylaryl; and one or two occurrences of R_1 represent hydrogen.

14. (**currently amended**) The method of claim 11, wherein A is a double bond; n = 2; and one occurrence of R_1 is selected from the group consisting of phenyl, 3,4-Dichloro-phenyl, 4-methoxy-phenyl, 4-fluoro-phenyl, 1-napthyl, 2-furyl, 3-furyl, ~~methoxy,~~ and substituted or unsubstituted alkenylaryl, and the second occurrence of R_1 is hydrogen, and the compound is an E (entgegen) isomer.

15. (**previously presented**) The method of claim 11, wherein said disorder in a human is associated with a deficiency in the concentration of serotonin or norepinephrine.

16. (**previously presented**) The method of claim 11, wherein said disorder in a human is selected from the group consisting of depression, substance addiction, neurodegenerative disease, Attention Deficit Disorder, Huntington's Disease, and bipolar disorder.

17. (**previously presented**) The method of claim 16, wherein said disorder in a human is Parkinson's Disease or Alzheimer's Disease.

18. (**previously presented**) The method of claim 16, wherein said substance addiction is cocaine addiction.

Claims 19-26. (**Canceled**)

27. (**currently amended**) A compound represented by formula **(II):**



(II)

wherein,

R_1 and R_2 each independently are selected from the group consisting of hydrogen, aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkenyl, and alkynyl;

R_3-R_{13} each independently are selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkoxy, [[-$C(O)R_8$]] -$\underline{C(O)R_{15}}$, amino, hydroxy, thio, halogen, cyano, nitro, trifluoromethyl, -N_3, [[-$C(R_8)$=NR_8; -N=$C(R_8)_2$, -$C(O)N(R_8)_2$, -Q_2-$P(Q_1)(OR_8)_2$,]] -$\underline{C(R_{15})=NR_{15}}$; -$\underline{N=C(R_{15})_2}$, -$\underline{C(O)N(R_{15})_2}$, -$\underline{Q_2\text{-}P(Q_1)(OR_{15})_2}$, -$SO_2R$, silyl, -$\underline{R_{16}OR_{15}}$, -$\underline{SR_{15}}$, and -$\underline{CO_2R_{15}}$ [[-R_9OR_8, -SR_8, and -CO_2R_8]];

R_{14} is selected from the group consisting of -$\underline{R_{16}C(O)OR_{15}}$, -$\underline{OC(O)R_{15}}$, $\underline{O\text{-}R_{17}}$, [[-$R_9C(O)OR$, -$OC(O)R$, $O\text{-}R_{15}$,]] wherein $\underline{R_{17}}$ [[R_{15}]] is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, alkenyl, and alkynyl; -$\underline{R_{16}(O)CR_{15}}$; -$\underline{C(R_{15})=N(OH)}$; carboxylic acid; -$\underline{R_{16}C(O)H}$; -$\underline{Q_2\text{-}P(Q_1)(OR_{15})_2}$; [[-$R_9(O)CR_8$; -$C(R_8)$=N(OH); carboxylic acid; -$R_9C(O)H$; -Q_2-$P(Q_1)(OR_8)_2$;]] and silyl;

$\underline{R_{15}}$ [[R_8]] represents independently for each occurrence hydrogen, alkyl, alkenyl, alkynyl, or aryl;

$\underline{R_{16}}$ [[R_9]] represents independently for each occurrence a bond or an alkyl, alkenyl, alkynyl, or aryl biradical;

Q_1 represents independently for each occurrence S or O; and

Q_2 represents independently for each occurrence O, S, or $\underline{NR_{15}}$; [[NR_8;]]

or a pharmaceutically acceptable salt thereof.

28. **(currently amended)** The compound of claim 27, wherein R_1 is selected from the group consisting of aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkenyl, and alkynyl, and R_2 is hydrogen, or R_2 is selected from the group consisting of aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkenyl, and alkynyl, and R_1 is hydrogen, and the compound is an E (entgegen) or Z (zusammen) isomer; R_3-R_{13} each independently represent hydrogen or alkyl; and R_{14} is $\underline{-R_{16}C(O)OR_{15}}$ or $\underline{-OC(O)R_{15}}$ [[-R_9C(O)OR or -OC(O)R]].

29. **(currently amended)** The compound of claim 27, wherein R_1 is selected from the group consisting of haloaryl, ~~alkoxy,~~ alkylaryl, polycyclyl, alkenylaryl, and alkynylaryl; and R_2 is hydrogen; or R_2 is selected from the group consisting of haloaryl, alkoxy, alkylaryl, polycyclyl, alkenylaryl, and alkynylaryl; and R_1 is hydrogen.

30. **(currently amended)** The compound of claim 27, wherein R_1 is selected from the group consisting of phenyl, 3,4-Dichloro-phenyl, 4-methoxy-phenyl, 4-fluoro-phenyl, 1-napthyl, 2-furyl, 3-furyl, ~~methoxy,~~ and substituted or unsubstituted alkenylaryl; and R_2 is hydrogen, and the compound is an E (entgegen) isomer.

31. **(currently amended)** The compound of claim 27, wherein R_1 is 4-methoxy-phenyl, R_2 is hydrogen, R_3-R_{13} each represent hydrogen, and R_{14} is $\underline{-R_{16}C(O)OR_{15}}$ or $\underline{-OC(O)R_{15}}$ [[-R_9C(O)OR or -OC(O)R]].

32. **(currently amended)** The compound of claim 27, wherein R_1 is phenyl, R_2 is hydrogen, R_3-R_{13} each represent hydrogen, and R_{14} is $\underline{-R_{16}C(O)OR_{15}}$ or $\underline{-OC(O)R_{15}}$ [[-R_9C(O)OR or -OC(O)R]].

33. **(currently amended)** A pharmaceutical composition comprising a compound of formula **(II):**



(II)

wherein,

R_1 and R_2 each independently are selected from the group consisting of hydrogen, aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkenyl, and alkynyl;

R_3-R_{13} each independently are selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkoxy, [[-$C(O)R_8$]] $\underline{-C(O)R_{15}}$, amino, hydroxy, thio, halogen, cyano, nitro, trifluoromethyl, -N_3, [[-$C(R_8)=NR_8$; -$N=C(R_8)_2$, -$C(O)N(R_8)_2$, -Q_2-$P(Q_1)(OR_8)_2$,]] $\underline{-C(R_{15})=NR_{15}}$; $\underline{-N=C(R_{15})_2}$, $\underline{-C(O)N(R_{15})_2}$, $\underline{-Q_2\text{-}P(Q_1)(OR_{15})_2}$, -$SO_2R$, silyl, $\underline{-R_{16}OR_{15}}$, $\underline{-SR_{15}}$, and $\underline{-CO_2R_{15}}$ [[-R_9OR_8, -SR_8, and -CO_2R_8]];

R_{14} is selected from the group consisting of $\underline{-R_{16}C(O)OR_{15}}$, $\underline{-OC(O)R_{15}}$, $\underline{O\text{-}R_{17}}$, [[-$R_9C(O)OR$, -$OC(O)R$, -$O\text{-}R_{15}$,]] wherein $\underline{R_{17}}$ [[R_{15}]] is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, alkenyl, and alkynyl; $\underline{-R_{16}(O)CR_{15}}$; $\underline{-C(R_{15})=N(OH)}$; $\underline{\text{carboxylic acid}}$; $\underline{-R_{16}C(O)H}$; $\underline{-Q_2\text{-}P(Q_1)(OR_{15})_2}$; [[-$R_9(O)CR_8$; -$C(R_8)=N(OH)$; carboxylic acid; -$R_9C(O)H$; -$Q_2$-$P(Q_1)(OR_8)_2$;]] and silyl;

$\underline{R_{15}}$ [[R_8]] represents independently for each occurrence hydrogen, alkyl, alkenyl, alkynyl, or aryl;

$\underline{R_{16}}$ [[R_9]] represents independently for each occurrence a bond or an alkyl, alkenyl, alkynyl, or aryl biradical;

Q_1 represents independently for each occurrence S or O; and

Q_2 represents independently for each occurrence O, S, or $\underline{NR_{15}}$; [[NR_8;]]

or a pharmaceutically acceptable salt thereof; and

a pharmaceutically acceptable carrier.

34. **(currently amended)** The pharmaceutical composition of claim 33, wherein R_1 is selected from the group consisting of aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkenyl, and alkynyl, and R_2 is hydrogen, or R_2 is selected from the group consisting of aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkenyl, and alkynyl, and R_1 is hydrogen, and the compound is an E (entgegen) or Z (zusammen) isomer; R_3-R_{13} each independently represent hydrogen or alkyl; and R_{14} is $-R_{16}C(O)OR_{15}$ or $-OC(O)R_{15}$ [[$-R_9C(O)OR$ or $-OC(O)R$]].

35. **(currently amended)** The pharmaceutical composition of claim 33, wherein R_1 is selected from the group consisting of haloaryl, ~~alkoxy,~~ alkylaryl, polycyclyl, alkenylaryl, and alkynylaryl; and R_2 is hydrogen; or R_2 is selected from the group consisting of haloaryl, alkoxy, alkylaryl, polycyclyl, alkenylaryl, and alkynylaryl; and R_1 is hydrogen.

36. **(currently amended)** The pharmaceutical composition of claim 33, wherein R_1 is selected from the group consisting of phenyl, 3,4-Dichloro-phenyl, 4-methoxy-phenyl, 4-fluoro-phenyl, 1-napthyl, 2-furyl, 3-furyl, ~~methoxy,~~ and substituted or unsubstituted alkenylaryl; and R_2 is hydrogen, and the compound is an E (entgegen) isomer.

37. **(currently amended)** A method for treating a disorder caused by a deficiency in monoamine concentration in a human comprising administering a therapeutically effective dose of a compound of formula **(II)**:



(II)

wherein,

R_1 and R_2 each independently are selected from the group consisting of hydrogen, aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkenyl, and alkynyl;

R_3-R_{13} each independently are selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkoxy, [[-$C(O)R_8$]] -$\underline{C(O)R_{15}}$, amino, hydroxy, thio, halogen, cyano, nitro, trifluoromethyl, -N_3, [[-$C(R_8)$=NR_8; -N=$C(R_8)_2$, -$C(O)N(R_8)_2$, -Q_2-$P(Q_1)(OR_8)_2$,]] -$\underline{C(R_{15})=NR_{15}}$; -$\underline{N=C(R_{15})_2}$, -$\underline{C(O)N(R_{15})_2}$, -$\underline{Q_2\text{-}P(Q_1)(OR_{15})_2}$, -$SO_2R$, silyl, -$\underline{R_{16}OR_{15}}$, -$\underline{SR_{15}}$, and -$\underline{CO_2R_{15}}$ [[-R_9OR_8, -SR_8, and -CO_2R_8]];

R_{14} is selected from the group consisting of -$\underline{R_{16}C(O)OR_{15}}$, -$\underline{OC(O)R_{15}}$, $\underline{O\text{-}R_{17}}$, [[-$R_9C(O)OR$, -$OC(O)R$, $O\text{-}R_{15}$,]] wherein $\underline{R_{17}}$ [[R_{15}]] is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, alkenyl, and alkynyl; -$\underline{R_{16}(O)CR_{15}}$; -$\underline{C(R_{15})=N(OH)}$; carboxylic acid; -$\underline{R_{16}C(O)H}$; -$\underline{Q_2\text{-}P(Q_1)(OR_{15})_2}$; [[-$R_9(O)CR_8$; -$C(R_8)$=$N(OH)$; carboxylic acid; -$R_9C(O)H$; -$Q_2$-$P(Q_1)(OR_8)_2$;]] and silyl;

$\underline{R_{15}}$ [[R_8]] represents independently for each occurrence hydrogen, alkyl, alkenyl, alkynyl, or aryl;

$\underline{R_{16}}$ [[R_9]] represents independently for each occurrence a bond or an alkyl, alkenyl, alkynyl, or aryl biradical;

Q_1 represents independently for each occurrence S or O; and

Q_2 represents independently for each occurrence O, S, or $\underline{NR_{15}}$; [[NR_8;]]

or a pharmaceutically acceptable salt thereof.

38. (**currently amended**) The method of claim 37, wherein R_1 is selected from the group consisting of aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkenyl, and alkynyl, and R_2 is hydrogen, or R_2 is selected from the group consisting of aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkenyl, and alkynyl, and R_1 is hydrogen, and the compound is an E (entgegen) or Z (zusammen) isomer; R_3-R_{13} each independently represent hydrogen or alkyl; and R_{14} is -$\underline{R_{16}C(O)OR_{15}}$ or -$\underline{OC(O)R_{15}}$ [[-$R_9C(O)OR$ or -$OC(O)R$]].

39. (**currently amended**) The method of claim 37, wherein either R_1 is selected from the group consisting of haloaryl, ~~alkoxy,~~ alkylaryl, polycyclyl, alkenylaryl, and alkynylaryl; and R_2 is hydrogen; or R_2 is selected from the group consisting of haloaryl, alkoxy, alkylaryl, polycyclyl, alkenylaryl, and alkynylaryl; and R_1 is hydrogen.

40. (**currently amended**) The method of claim 37, wherein R_1 is selected from the group consisting of phenyl, 3,4-Dichloro-phenyl, 4-methoxy-phenyl, 4-fluoro-phenyl, 1-napthyl, 2-furyl, 3-furyl, ~~methoxy,~~ and substituted or unsubstituted alkenylaryl; and R_2 is hydrogen, and the compound is an E (entgegen) isomer.

41. (**previously presented**) The method of claim 37, wherein said disorder in a human is associated with a deficiency in the concentration of serotonin or norepinephrine.

42. (**previously presented**) The method of claim 37, wherein said disorder in a human is selected from the group consisting of depression, substance addiction, neurodegenerative disease, Attention Deficit Disorder, Huntington's Disease, and bipolar disorder.

43. (**previously presented**) The method of claim 42, wherein said disorder in a human is Parkinson's Disease or Alzheimer's Disease.

44. (**previously presented**) The method of claim 42, wherein said substance addiction is cocaine addiction.

Claims 45-59. (**Canceled**)